PTC Therapeutics Inc
PTCTHealthcare|Biotechnology|USA
$84.85
-4.70 (-5.25%)
Financials
Financial Snapshot
Market Cap
$7.04B
Enterprise Value
$1.50B
Revenue (TTM)
$827.1M
Net Income (TTM)
$-186.7M
Cash & Equivalents
—
Net Cash/Share
$-13.96
Free Cash Flow (TTM)
$-516.8M
Operating CF (TTM)
$-217.9M
Debt/Equity
-2.19
Cash Runway & Burn Rate
Cash on Hand
$0.00
Quarterly Burn
$54.5M
Monthly Burn
$18.2M
Est. Runway
—
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $231.7M | $191.2M | $227.6M | $686.6M | $1.10B | $773.4M | $410.7M | $876.7M | $1.14B | $1.95B | $1.89B | |
| Operating Cash Flow | $-103.6M | $-10.1M | $-27.6M | $-98.6M | $-194.1M | $-251.3M | $-356.7M | $-158.4M | $-107.7M | $711.2M | $-217.9M | |
| Free Cash Flow | $-105.3M | $-90.3M | $-43.2M | $-144.1M | $-250.0M | $-336.7M | $-509.1M | $-279.0M | $-181.9M | $411.2M | $-516.8M | |
| Capital Expenditure | $-1.8M | $-80.3M | $-15.5M | $-45.4M | $-56.0M | $-85.3M | $-152.5M | $-120.6M | $-74.2M | $-300.0M | $-298.8M | |
| Financing Cash Flow | $968.0K | $44.2M | $131.6M | $613.2M | $668.7M | $20.9M | $168.0M | $646.4M | $255.9M | $331.1M | $328.1M |
R&D Spending
R&D (TTM)
$447.1M
R&D Intensity
54.1%
R&D Growth YoY
-1.8%
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $82.7M | $194.4M | $264.7M | $307.0M | $380.8M | $538.6M | $698.8M | $937.8M | $806.8M | $1.73B | $827.1M | |
| R&D Expense | $117.6M | $117.5M | $172.0M | $257.5M | $477.6M | $540.7M | $651.5M | $666.6M | $534.5M | $455.2M | $447.1M | |
| R&D % of Revenue | 142.2% | 60.4% | 65.0% | 83.9% | 125.4% | 100.4% | 93.2% | 71.1% | 66.2% | 26.3% | 54.1% | |
| SG&A | $97.1M | $121.3M | $153.5M | $202.5M | $245.2M | $285.8M | $326.0M | $332.5M | $300.9M | $347.1M | $352.4M |
Income Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $82.7M | $194.4M | $264.7M | $307.0M | $380.8M | $538.6M | $698.8M | $937.8M | $806.8M | $1.73B | $827.1M | |
| Cost of Goods Sold | $0.00 | $4.6M | $12.7M | $12.1M | $18.9M | $32.3M | $44.7M | $65.5M | $57.4M | $47.0M | $62.2M | |
| Gross Profit | $82.7M | $189.8M | $252.1M | $294.8M | $361.8M | $506.3M | $654.1M | $872.3M | $749.4M | $1.68B | $764.9M | |
| R&D | $117.6M | $117.5M | $172.0M | $257.5M | $477.6M | $540.7M | $651.5M | $666.6M | $534.5M | $455.2M | $447.1M | |
| SG&A | $97.1M | $121.3M | $153.5M | $202.5M | $245.2M | $285.8M | $326.0M | $332.5M | $300.9M | $347.1M | $352.4M | |
| Operating Income | $-132.1M | $-64.3M | $-96.3M | $-192.8M | $-397.9M | $-374.9M | $-439.9M | $-349.4M | $-146.7M | $856.5M | $-67.1M | |
| Interest Expense | $-8.3M | $-12.1M | $-12.6M | $-12.5M | $-56.4M | $-86.0M | $-90.9M | $-129.2M | $-167.0M | $-152.2M | $-167.2M | |
| Pretax Income | $-141.5M | $-77.7M | $-128.1M | $-239.9M | $-402.9M | $-518.3M | $-587.5M | $-696.1M | $-363.1M | $696.6M | $-235.7M | |
| Net Income | $-142.1M | $-79.0M | $-128.1M | $-251.6M | $-438.2M | $-523.9M | $-559.0M | $-626.6M | $-363.3M | $682.6M | $-186.7M | |
| EPS (Diluted) | -4.17 | -2.02 | -2.75 | -4.27 | -6.64 | -7.43 | -7.79 | -8.37 | -4.73 | 8.58 | -2.33 | |
| EBITDA | $-128.8M | $-46.6M | $-89.5M | $-195.3M | $-303.1M | $-368.2M | $-367.8M | $-330.3M | $-120.5M | $887.7M | $-21.5M | |
| Shares Out. (M) | 34.05 | 39.18 | 46.58 | 58.86 | 66.03 | 70.47 | 71.73 | 74.84 | 76.84 | 88.31 | 82.52 |
Balance Sheet
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $58.3M | $111.8M | $169.5M | $288.0M | $208.8M | $189.7M | $279.8M | $594.0M | $779.7M | $984.6M | $834.0M | |
| Marketable Securities | $173.3M | $79.5M | $58.1M | $398.5M | $894.8M | $583.7M | $130.9M | $282.7M | $360.0M | $960.7M | $1.06B | |
| Total Current Assets | $261.3M | $249.1M | $320.9M | $779.3M | $1.23B | $954.4M | $693.8M | $1.22B | $1.37B | $2.27B | $2.25B | |
| Total Assets | $269.3M | $391.7M | $1.12B | $1.62B | $2.21B | $1.94B | $1.71B | $1.90B | $1.71B | $2.90B | $2.87B | |
| Total Current Liabilities | $49.6M | $82.0M | $166.8M | $235.9M | $277.3M | $509.3M | $406.2M | $603.1M | $581.0M | $968.4M | $923.6M | |
| Long-Term Debt | $98.2M | $145.0M | $141.3M | $293.9M | $309.1M | $956.6M | $1.26B | $1.90B | $2.11B | $2.03B | $0.00 | |
| Total Liabilities | $149.8M | $235.2M | $768.5M | $1.03B | $1.73B | $1.94B | $2.05B | $2.71B | $2.80B | $3.10B | $3.05B | |
| Stockholders' Equity | $119.6M | $156.4M | $350.7M | $594.3M | $482.0M | $1.4M | $-347.1M | $-818.6M | $-1.10B | $-205.3M | $-180.5M | |
| Retained Earnings | $-735.1M | $-814.1M | $-938.9M | $-1.19B | $-1.63B | $-2.10B | $-2.66B | $-3.28B | $-3.65B | $-2.96B | $-2.97B |
Cash Flow Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $-103.6M | $-10.1M | $-27.6M | $-98.6M | $-194.1M | $-251.3M | $-356.7M | $-158.4M | $-107.7M | $711.2M | $-217.9M | |
| Capital Expenditure | $-1.8M | $-80.3M | $-15.5M | $-45.4M | $-56.0M | $-85.3M | $-152.5M | $-120.6M | $-74.2M | $-300.0M | $-298.8M | |
| Free Cash Flow | $-105.3M | $-90.3M | $-43.2M | $-144.1M | $-250.0M | $-336.7M | $-509.1M | $-279.0M | $-181.9M | $411.2M | $-516.8M | |
| Investing Cash Flow | $104.5M | $13.1M | $-42.6M | $-387.2M | $-561.5M | $219.2M | $290.2M | $-176.7M | $44.2M | $-862.0M | $-771.4M | |
| Financing Cash Flow | $968.0K | $44.2M | $131.6M | $613.2M | $668.7M | $20.9M | $168.0M | $646.4M | $255.9M | $331.1M | $328.1M | |
| Issuance of Stock | $0.00 | $0.00 | $117.9M | $323.8M | $28.1M | $0.00 | $50.0M | $0.00 | $0.00 | $0.00 | $0.00 | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Issuance of Debt | $0.00 | $40.0M | $0.00 | $279.3M | $0.00 | $0.00 | $300.0M | $0.00 | $0.00 | $0.00 | $0.00 | |
| Payments of Debt | $0.00 | $0.00 | $0.00 | $-11.7M | $-46.2M | $-2.2M | $-151.3M | $-301.4M | $-1.5M | $-1.6M | $-1.6M | |
| Stock Based Comp. | $35.0M | $30.6M | $33.3M | $42.1M | $70.3M | $103.5M | $110.3M | $131.2M | $74.6M | $74.5M | $79.9M | |
| Net Change in Cash | $299.0K | $53.5M | $57.7M | $126.0M | $-79.2M | $-19.1M | $98.7M | $314.4M | $185.0M | $203.0M | $-645.4M |
Dilution Tracker
Shares Outstanding
83M
5-Year Share Growth
+17.1%
Stock Issuance (TTM)
$0.00
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 34.05 | 39.18 | 46.58 | 58.86 | 66.03 | 70.47 | 71.73 | 74.84 | 76.84 | 88.31 | 82.52 | |
| YoY Change % | — | 15.1% | 18.9% | 26.4% | 12.2% | 6.7% | 1.8% | 4.3% | 2.7% | 14.9% | -6.6% | |
| Stock Issuance | $0.00 | $0.00 | $117.9M | $323.8M | $28.1M | $0.00 | $50.0M | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $35.0M | $30.6M | $33.3M | $42.1M | $70.3M | $103.5M | $110.3M | $131.2M | $74.6M | $74.5M | $79.9M |
Margins & Profitability
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 0.0% | 97.6% | 95.2% | 96.0% | 95.0% | 94.0% | 93.6% | 93.0% | 92.9% | 97.3% | 92.5% | |
| Operating Margin % | -159.7% | -33.1% | -36.4% | -62.8% | -104.5% | -69.6% | -63.0% | -37.3% | -18.2% | 49.5% | -8.1% | |
| Net Margin % | -171.8% | -40.6% | -48.4% | -82.0% | -115.1% | -97.3% | -80.0% | -66.8% | -45.0% | 39.4% | -22.6% | |
| EBITDA Margin % | -155.7% | -24.0% | -33.8% | -63.6% | -79.6% | -68.4% | -52.6% | -35.2% | -14.9% | 51.3% | -2.6% | |
| FCF Margin % | -127.4% | -46.5% | -16.3% | -46.9% | -65.7% | -62.5% | -72.9% | -29.8% | -22.6% | 23.8% | -62.5% | |
| ROE % | -82.2% | -57.2% | -50.5% | -53.2% | -81.4% | -216.7% | 0.0% | 0.0% | 0.0% | Negative Equity | 0.0% | |
| ROA % | -44.8% | -23.9% | -17.0% | -18.3% | -22.9% | -25.3% | -30.7% | -34.8% | -20.2% | 29.7% | -6.8% | |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - | - |
Valuation
P/E (TTM)At Loss
HistoricalAt Loss / 8.00 / 10.05
Industry Med.27.41
P/S8.66
Historical1.72 / 5.24 / 12.18
Industry Med.9.51
P/B—
Historical1.22 / 5.46 / 2187.50
Industry Med.2.93
EV/EBITDA-257.76
Historical-257.76 / -9.93 / 8.94
Industry Med.13.14
EV/Revenue6.70
Historical0.27 / 5.26 / 11.15
Industry Med.8.71
P/FCF—
Historical5.66 / 13.52 / 2155.26
Industry Med.27.54
Intrinsic Value Models
Median P/S Value
$53.09
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PE Ratio | At Loss | At Loss | At Loss | At Loss | At Loss | At Loss | At Loss | At Loss | At Loss | 8.85 | At Loss | |
| PS Ratio | 4.49 | 3.36 | 6.04 | 9.21 | 10.58 | 5.21 | 3.92 | 2.20 | 4.30 | 3.88 | 8.66 | |
| PB Ratio | 3.12 | 4.44 | 4.95 | 5.01 | 8.83 | 1991.50 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| EV/EBITDA | -1.86 | -13.90 | -18.58 | -13.40 | -11.78 | -9.01 | -10.44 | -10.41 | -40.17 | 7.83 | -257.76 | |
| EV/Revenue | 2.89 | 3.33 | 6.28 | 8.52 | 9.38 | 6.16 | 5.50 | 3.67 | 6.00 | 4.02 | 6.70 |
Analyst Estimates & Quality
Altman Z-Score
0.70
Distress
Piotroski F-Score
2
Weak
Beneish M-Score
-1.60
Possible Manipulator
Forward Estimates
| Metric | Current Year | Next Year | 2 Years Out |
|---|---|---|---|
| Revenue | $1,187.3M | $1,356.2M | $1,643.8M |
| Net Income | $110.7M | $246.4M | $395.4M |
| EPS | 0.39 | 1.26 | 4.38 |
| Book Value per Share | 1.66 | 5.38 | 14.33 |
| Operating Cash Flow per Share | 2.00 | 3.25 | 0.00 |
| Operating CF | $164.63M | $267.78M | $0.00M |
Dividends
Revenue Segments
By Business
| Segment | 2025 |
|---|---|
| Collaboration and license revenue | $998.4M |
| All other products | $37.3M |
| Emflaza | $146.4M |
| Royalty revenue | $244.2M |
| Sephience | $111.2M |
| Translarna | $235.3M |
| Translarna France | $-98.6M |
| Upstaza/Kebilidi | $56.6M |
By Geography
| Segment | 2025 |
|---|---|
| United States | $1.49B |
| Non - United States (US) | $235.9M |